Supplementary Figures S1-S10 from NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS–MAPK Pathway in Neuroblastoma

MLA

Meredith S. Irwin, et al. Supplementary Figures S1-S10 from NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS–MAPK Pathway in Neuroblastoma. Mar. 2023. EBSCOhost, https://doi.org/10.1158/0008-5472.22423409.v1.

APA

Meredith S. Irwin, Michael Ohh, Yoshihito Kano, Claire M. Robinson, Gabriella Christopher, Teresa Adderley, Lynn Kee, Yagnesh Ladumor, & Ivette Valencia-Sama. (2023). Supplementary Figures S1-S10 from NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS–MAPK Pathway in Neuroblastoma. https://doi.org/10.1158/0008-5472.22423409.v1

Chicago

Meredith S. Irwin, Michael Ohh, Yoshihito Kano, Claire M. Robinson, Gabriella Christopher, Teresa Adderley, Lynn Kee, Yagnesh Ladumor, and Ivette Valencia-Sama. 2023. “Supplementary Figures S1-S10 from NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS–MAPK Pathway in Neuroblastoma,” March. doi:10.1158/0008-5472.22423409.v1.